GlassScriptPhysician profile
Bradley L Rosenberg
NPI 1679591168
$10,888.31
in general payments reported to CMS, 2019-2025
32 companies · $1,056 in 2025
The $1,056 reported for 2025 was more than what 87% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $274 · 2020: $999 · 2021: $1,042 · 2022: $1,565 · 2023: $2,632 · 2024: $3,321 · 2025: $1,056.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,857 · Education: $152.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,857.43 |
| Education | $151.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $3,347.33 | 2020-2025 | Breztri, Farxiga, Airsupra |
| Abbvie INC. | $1,747.68 | 2021-2025 | Qulipta, Vraylar, Ubrelvy |
| Glaxosmithkline, LLC. | $815.22 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $782.81 | 2019-2025 | |
| Lilly USA, LLC | $607.50 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $583.77 | 2019-2025 | Jardiance, Spiriva Respimat, Stiolto Respimat |
| Novo Nordisk INC | $583.11 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Phathom Pharmaceuticals, INC. | $270.06 | 2024-2025 | Voquezna |
| Amgen INC. | $254.17 | 2020-2025 | Repatha, Otezla, Otezla |
| Amarin Pharma, INC. | $243.90 | 2020-2023 | |
| Allergan, INC. | $237.40 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $157.67 | 2020-2024 | Trintellix |
| Bayer Healthcare Pharmaceuticals INC. | $135.33 | 2021-2024 | |
| Corcept Therapeutics | $133.99 | 2023-2025 | Korlym |
| Azurity Pharmaceuticals, INC. | $127.90 | 2023-2025 | Horizant, Edarbi, Edarbyclor |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $109.68 | 2020-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $88.23 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $86.52 | 2022-2025 | Xifaxan |
| Lundbeck LLC | $84.69 | 2024-2025 | Rexulti |
| Idorsia Pharmaceuticals US INC | $75.64 | 2023-2024 | Quviviq |
| Horizon Therapeutics Plc | $70.13 | 2020-2022 | |
| Teva Pharmaceuticals USA, INC. | $56.75 | 2020-2022 | |
| Arbor Pharmaceuticals, INC. | $50.67 | 2019-2021 | |
| Amneal Pharmaceuticals LLC | $48.85 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $34.97 | 2019-2025 | Eliquis |
| Kowa Pharmaceuticals America, INC. | $31.84 | 2020-2021 | |
| Assertio Therapeutics, INC. | $23.74 | 2020 | |
| Biohaven Pharmaceuticals, INC. | $23.71 | 2021 | |
| Merck Sharp & Dohme LLC | $20.64 | 2020 | |
| Exact Sciences Corporation | $19.72 | 2023 | Cologuard Collection Kit |
| Impel Pharmaceuticals INC. | $17.56 | 2023 | Trudhesa |
| Genentech USA, INC. | $17.13 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bradley Rosenberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.